glp 1 approved for prediabetes GLP-1 Costs Explained: Managing Coverage Challenges Access to GLP-1s for Medicare
Description
GLP-1RAs are currently used for treating type 2 diabetes and obesity due to their effects on appetite, food intake, and weight loss
The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists, or GLP-1s, at $200 and counts the spending toward annual deductibles, the company announced in a news release today
triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial
Daily Value not established
The most widely cited early dataset is a Phase 2 trial in adults with obesity/overweight without diabetes, published in 2023
